DTILEarnings•businesswire•
Precision BioSciences to Report Second Quarter 2025 Results on August 7, 2025
Sentiment:Negative (10)
Summary
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for diseases with high unmet need, today announced that it will publish financial results for the second quarter 2025 and provide a business update on August 7, 2025. About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical stage gene editing company dedicated to improving lif
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 4, 2025 by businesswire